Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure

Heart Failure Clinical Trial

— TAME-HF  

Official title:

Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01820130
• Other study ID #: CR-12-047-FR-SC
• Status: Withdrawn
• Phase: N/A
• Start date: March 2013
• Est. completion date: September 2016

Study information

• Verified date: February 2019
• Source: Abbott Medical Devices
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical investigation is to evaluate the safety and efficacy of Spinal Cord Stimulation (SCS) in advanced heart failure (HF) patients with Implantable Cardioverter Defibrillator (ICD) but not indicated for Cardiac Resynchronization Therapy (CRT).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients has a Left Ventricular Ejection Fraction (LVEF) less than or equal to 35%

• Patient is in New York Heart Association (NYHA) Class III

• Patient has a QRS duration <120 ms (non-paced QRS, at the time of device Implant or protocol inclusion)

• Patient has had an ICD implanted for >90 days

• Patient is receiving stable and optimal medical therapy for HF (>90 days) as describe by "European Society of Cardiology 2012 recommendation for diagnosis and treatment of acute and chronic Heart Failure", except in case of contraindication or allergy

• Patient is able to provide written Informed Consent prior to any investigational related procedure

Exclusion Criteria:

• Patient currently has an implanted spinal cord stimulator or previously had an implanted spinal cord stimulator which is now explanted or has had previous spinal surgery that would interfere with implant of percutaneous SCS leads in the upper thoracic region

• Patient has polyneuropathy

• Patient requires short-wave diathermy, microwave diathermy or therapeutic ultrasound diathermy

• Patient is in NYHA class IV

• Patient has received a tissue / organ transplant or is expected to have a tissue / organ transplant within the next 180 days

• Patient has a cardiac resynchronization therapy (CRT) device, or LV Assist device or is expected to receive CRT, or left ventricular assist device (LVAD) within the next 180 days

• Patient has critical valvular heart disease that requires valve repair or replacement

• Patient has had a myocardial infarction (MI) or cardiac revascularization procedure (percutaneous coronary intervention or coronary artery bypass graft) within 90 days of enrollment

• Patient is on IV inotropic therapy

• Patient has active myocarditis or early postpartum cardiomyopathy

• Patient has taken any of the following drugs within 30 days of enrollment: systemic corticosteroids, cytostatic and immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), DNA depleting or cytotoxic drugs

• Patient is pregnant, or of childbearing potential and is not using adequate contraceptive methods, or nursing

• Patient with a bleeding tendency (INR >1.2 and platelet count <100 x109 per liter)

• Patient has a local infection at the ICD implant location or systemic infection

• Patient has renal insufficiency (creatinine >3.0 mg/dl)

• Patient with risk of allergy to SCS device component materials

• Patient having one of the following condition must be considered as non relevant for SCS implantation:

1. / Patient with active stent

2. / Patient having bare metal stent for less than 6 months

3. / Patient presented with an acute coronary syndrome within the last 6 months

4. / Patient with stent on the common

5. / Patient with a history of stent thrombosis

6. / Coronary Patient receiving double antiplatelet medication

• Patient is participating in another clinical study with an active treatment arm

• Patient is less than 18 years old

• Patient's life's expectancy is less than 1 year as assessed by investigators

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• St Jude Medical EON mini rechargeable system
implantation of Eon Mini Neurostimulation System (IPG Model 3788)

Locations

Country	Name	City	State
France	CHU	Pessac

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy Marker of Cardiac remodeling via Left Ventricular End Diastolic Volume (LVEDV) of Patient with advanced HF	Evaluation of left ventricular end diastolic volume (LVEDV) as measured by cardiac echo between baseline and after 6 months of SCS therapy.	baseline and 6 Months
Primary	Efficacy Marker of patient symptom via NYHA class for patient with advanced HF	Evaluation of NYHA class as marker of patient symptom between baseline and after 6 months of SCS therapy.	Baseline and 6 months
Primary	Efficacy Marker of patient symptom via 6 Minutes Hall Walk distance for patient with advanced HF	Evaluation of 6 Minutes Hall walk (6MHW) as marker of patient symptom between baseline and after 6 months of SCS therapy.	baseline to 6 months
Secondary	Safety composite marker of SCS therapy for patient with HF and ICD device	Report of cardiovascular event, arrythmias, devices interaction, procedural and post-procedural events analyzed in a global composite way.	baseline and 6 months
Secondary	Additional efficacy markers of SCS therapy on patient symptom via Quality Of Life questionnaire	Endpoint measurements of patient-reported quality of life after 6 months of therapy.	baseline to 6 months
Secondary	Additional efficacy markers of SCS therapy on patient symptom via Maximal exercise test tolerance	Additional endpoint measurements include exercise tolerance between baseline and 6 months via cardiopulmonary test, including maximum level of exercise and heart rhythm.	baseline and 6 months
Secondary	Additional efficacy markers of SCS therapy on cardiac function via echocardiography	Additional endpoint measurements include standard echocardiography markers of LV structure and function including systolic and diastolic performance and cardiac dimensions as a marker of structural reverse remodeling	baseline and 6 months